MB-PMRB@EC2605A

Norges Bank Sells 1,834,200 Shares of Kanglong Chemical

Norges Bank 增持康龙化成股份至 6.09%

Kelong Chemicals Completes Placement to Raise HKD 1.319 Billion

Kanglong Chemicals' Stock Price Drops After Rights Issue

Kanglong Chemical Starts HKG Equity Offering, Raises HKD 1.32 Billion Net

Kanglong Chemical Beijing Conducts 58.44 Million H-shares Private Placement

CLSA Analyzes Kanglong Chemical's Q4 2025 Results and Maintains Buy Rating

Konlon Chemical Reveals Full-Year Net Profit Preliminary Data Ranging from 161 million to 169 million Yuan

Kanglong Chemical Predicts Decline in Net Profit but Revenue Growth in 2025

Norges Bank reduces holdings in Kanglong Chem 3,659,500 shares

JPMorgan Increases Stake in Canbridge Pharma to 5.24% by Acquiring 1.456M Shares

Kangbok Chemical's Shareholders Reduce Holdings by 18.4819 million Shares

Kanglong Chem Beijing Co., Ltd. Holds Extraordinary General Meeting and Approves Multiple Resolutions

Kangbok Chemical Shareholders Reduce Holdings by 1%

Kanglong Chemical Beijing Co., Ltd Acquires Biortus to Enhance Its CRO Market Position

Kanglong Huacheng Acquires Bayoreader for 1346 Million Yuan

Cinda International Securities Upgrades Kanglong Chemical's Rating and Target Price

Convergent Science's Shareholders Plan to Reduce Holdings

Major Shareholders of Kanglong Chemical Plan to Reduce Shareholding

Norges Bank Increases Holdings in ChemPartner

STARCOIN GROUP

DAISHOMICROLINE

IDT INT'L

GUANZE MEDICAL

BOER POWER

KNOWLEDGE ATLAS

CHINA INFO TECH

QINGHUA HOLD

SUPER STRONG

HAIZHI TECH GP

520500

159992

RLAY

159570

159316

513120

513700

03759

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

Wallstreetcn

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Relay Therapeutics

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

Lantern Pharma

Hwabao WP CSI Medical Service ETF

WUXI APPTEC

E Fund CSI 300 Health Care ETF

YieldMax AI Option Income Strategy ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Yinhua CNI HK Connect Innovative Drugs ETF

ICBCCS SSE STAR Biology and Medicine ETF

Recursion Pharmaceuticals

Abcellera Biologics

ChinaAMC CSI Biotechnology Theme ETF

Tempus AI

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

ChinaAMC CSI All Share Health Care Devices ETF

Exact Sciences

Penghua CSI HK Connect Health Care Composite ETF

Marinus Pharma

iShares US Pharma

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

VanEck Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

iShares US Healthcare Providers

Ping An CSI Medicine and Medical Device Innovation ETF

Ark Genomic Revolution ETF

SPDR S&P Health Equip

PHARMARON

Neumora Therapeutics

Absci

Health Care Select Sector SPDR

Moderna

VG Health

WuXi AppTec

Pharmaron Beijing Co. Ltd. has filed a disclosure with the Hong Kong Stock Exchange regarding the issuance of 81,643 new A shares to employees under its 2021 Restricted A Share Incentive Scheme. The shares were issued at a price of RMB 30.39 each, increasing the total share capital to 1,476,658,400 shares. This announcement is part of the company's ongoing incentive program for employees.

Reuters

Pharmaron Beijing Files HKEX Disclosure on Share Capital Increase to 1,476,658,400 Shares at Undisclosed Price

Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at HK$22.82 per share. The funds will be used for expanding project development, increasing laboratory services and drug manufacturing capabilities, and for debt repayment. Following this transaction, the proportion of H shares increased from 16.62% to 19.28%, slightly diluting existing holdings. The company's market cap is HK$56.88 billion, with a current analyst rating of Hold and a price target of HK$24.00.

Tip Ranks

Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion

520690

520880

Pharmaron Beijing Completes HK$1.32 Billion Share Offering

marketscreener

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Pharmaron Beijing Completes HK$1.32 Billion Share Offering

Pharmaron Beijing Co. Ltd. has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange regarding changes in its issued H shares. The filing includes details on the total number of new shares issued and the volume-weighted average price per share, although specific figures were not disclosed. This announcement is part of the company's corporate announcement information.

Pharmaron Beijing Files HKEX Disclosure on Share Capital Increase With (X) New Shares Issued at (HK$X.XX) Each

300759

Pharmaron opened down 3.37% today, with a low of 23.02 yuan. It is currently reported at 24 yuan, down 3.77%, with a trading volume of 6.4042 million shares, involving 152 million yuan. The company recently announced a placement of nearly 58.4408 million new H shares at a discount of 8.5%, expected to raise nearly 1.32 billion yuan, of which 70% will be used for project construction to enhance laboratory service facilities, drug process development, and production capacity

AASTOCKS

Pharmaron

Pharmaron's stock price fell over 3%, with a discount of 8.5% on the placement

Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering

Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering

Pharmaron Beijing Co Ltd :TO PLACE 58.4 MILLION NEW H SHARES AT RMB1.00 PER SHARE

Pharmaron Beijing To Place 58.4 Million New H Shares At RMB1.00 Per Share

Pharmaron Beijing Co Ltd :SAYS IT PLANS TO PLACE 58.4 MILLION NEW H-SHARES AT HK$22.82 PER SHARESAYS IT EXPECTS TO RAISE ABOUT HK$1.3 BILLION ($166.74 million) FROM SHARE PLACEMENT TO FUND PROJECT CONSTRUCTION, REPAY BANK LOANS, BOOST CAPITAL($1 = 7.7966 Hong Kong dollars)

Pharmaron To Raise HK$1.3 Billion in Share Placement

Pharmaron Beijing Co. Ltd. has announced a private placement of 58,440,762 new H shares under its general issuance mandate. The company has signed a placing agreement with agents to procure subscribers for the shares. This placement is not registered in the U.S. and does not constitute a public offering there. An application will be made for listing on the Hong Kong Stock Exchange, but completion is subject to conditions, advising caution to shareholders and potential investors.

Pharmaron Beijing Announces Private Placement of 58 Million New H Shares

The report from Citi indicates that Pharmaron's net profit in the fourth quarter of 2025 exceeded expectations, with revenue increasing by 15% year-on-year and adjusted net profit growing by 16% annually. It is expected that the full-year revenue and net profit for 2025 will increase by 14.5% and 12.5%, respectively. The small molecule CDMO business will be the core growth engine in the future. Citi forecasts a 15% revenue growth in 2026 and maintains an "outperform" rating on Pharmaron, with a target price of 28.8 yuan

In "The Big Banks," Citigroup: Pharmaron's net profit last season exceeded expectations

Pharmaron Beijing sees 2025 net profit down 6-10%

Pharmaron Beijing sees 2025 net profit down 6-10%

Hong Kong stocks opened high and moved higher, with technology stocks and pharmaceutical stocks rising together. The technology index rose 2.35%, Tencent Music surged more than 15% after earnings, and Alibaba rose more than 4%.

BABA-WR

BABA-W

Alibaba HK SDR 5to1

Alibaba

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Tencent Music

TME-SW

FI2 CSOP HSI

VIVA BIOTECH

JOINN

Asymchem

CHINA LIT

CANBRIDGE-B

MEITUAN

MEITUAN-WR

Meituan HK SDR 5to1

Meituan

XI2CSOPHSTECH

XIAOMI-W

XIAOMI-WR

Xiaomi HK SDR 2to1

Xiaomi Corporation

KUAISHOU-W

KUAISHOU-WR

FIT HON TENG

BYD ELECTRONIC

AB&B BIO-TECH-B

BEONE MEDICINES

BeOne Medicines

Beigene

BILIBILI-W

Bilibili

BIDU-SW

BIDU-SWR

Baidu

FL2 CSOP HSI

Q TECH

JD-SW

JD-SWR

JD HK SDR 10to1

JD.com

AAC TECH

WEIMOB INC

XL2CSOPHSTECH

INNOVENT BIO

Hong Kong stock hot trading (8.13)｜ Hong Kong technology stocks fully exploded, Tencent hit a four-year high, Alibaba surged over 4%

$XTALPI(02228.HK)Short selling data this morning: 02228 Pharmaron (Beijing) Co., Ltd.－P 705,000 5,143,150. Average selling price 7.29 I expect the closing price to be above this level.

XTALPI

$XTALPI(02228.HK)Today's trend is &#34;not good-looking&#34;. Let's look at the data, short selling:  2228  Pharmaron－P         277,000      2,131,420 This small proportion of volume is not the reason why the price can't go up or the driving force for the decline. Today's trading volume is 100 million shares. We'll check the changes in the holdings of the Hong Kong Stock Connect (currently the hypothetical largest liquidity controller) tomorrow morning.

$XTALPI(02228.HK)We should still keep playing Pharmaron recently. The US stocks are also freaking hot as hell. 😜

$XTALPI(02228.HK) Short interest data this morning: 2228 Pharmaron (Beijing) Co., Ltd.－P         475,000      3,516,420 Average price: HK$7.4. This idiot has already lost HK$0.6 now.....

$XTALPI(02228.HK) Way to go! Just to prove them wrong! I'm going to get a client for Pharmaron. I mean, get a contract for 2228 for the company. md

$XTALPI(02228.HK) plans to sell some of the farmer's shares and buy Pharmaron today. That's the current plan.

$XTALPI(02228.HK) Didn't see @Stock God Xiao Gu buy Pharmaron. Don't panic, set up a long snake formation, stay calm, attack in three stages, take turns firing, the shorts won't reach us.

$XTALPI(02228.HK)So many people are worried about the market rising tomorrow, but Pharmaron might fall instead? I really want to open a betting pool and gamble with everyone. For example, each person can bet 50 HKD. Bet on whether it will rise or fall. Let's stare blankly and wait for the closing price. Hahaha.

$XTALPI(02228.HK) $NONGFU SPRING(09633.HK) Don't feel like talking. Maybe it's the numbness from reaching a stage high? 😁 My mind keeps flooding with one impulse - should I sell Nongfu to buy more Pharmaron. Sigh, holding stocks is really hard.

NONGFU SPRING

MB-PMRB@EC2605A(22362.HK)

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

Pharmaron Beijing Files HKEX Disclosure on Share Capital Increase to 1,476,658,400 Shares at Undisclosed Price

Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion

Pharmaron Beijing Completes HK$1.32 Billion Share Offering

Pharmaron Beijing Files HKEX Disclosure on Share Capital Increase With (X) New Shares Issued at (HK$X.XX) Each